| Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria (NCT05170724) | Novartis Pharmaceuticals | |
| Fecal Microbiota Transplantation (FMT): PRIM-DJ2727 (NCT03786900) | Herbert DuPont, MD | |
| Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies (NCT04457687) | Eisai Inc. | |
| Expanded Access to ABBV-CLS-484 (NCT06188975) | Calico Life Sciences LLC | |
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain (NCT03419949) | Assiut University | |
| Individual Patient Compassionate Use of Fedratinib (NCT03723148) | Celgene | |
| Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells (NCT01267461) | Meir Medical Center | |
| Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population (NCT04586062) | Kedrion S.p.A. | |
| Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies (NCT07346105) | Orca Biosystems, Inc. | |
| "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy." (NCT07238062) | Hope Biosciences Research Foundation | |
| Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds (NCT06730022) | Merakris Therapeutics | |
| Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (NCT04768907) | MaaT Pharma | |
| Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC (NCT03145545) | Children's Hospital of Philadelphia | |
| Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement (NCT04432545) | Universidad de la Sabana | |
| Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor (NCT07262970) | Rezolute | |
| Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tissue Collection (NCT06509828) | Avobis Bio, LLC | |
| Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients (NCT05014607) | University Hospital Tuebingen | |
| Doxecitine and Doxribtimine-Expanded Access (NCT06590493) | UCB BIOSCIENCES, Inc. | |
| Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients (NCT06802328) | Tiziana Life Sciences LTD | |
| Managed Access Programs for VAY736, Ianalumab (NCT07244289) | Novartis Pharmaceuticals | |
| Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP (NCT05067166) | Ridgeback Biotherapeutics, LP | |
| Intermediate-size Patient Population Expanded Access Protocol (NCT07088159) | Spinogenix | |
| BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency (NCT07422389) | BRIM Biotechnology Inc. | |
| Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients (NCT05974410) | AVM Biotechnology Inc | |
| Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors (NCT06797362) | Nuvalent Inc. | |
| Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval (NCT06751524) | Agenus Inc. | |
| Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients (NCT01216124) | Fudan University | |
| Comparison of Clinical Outcomes of IVUS -Guided and Angiography-guided PCI in Patients With Acute STEMI (NCT04929158) | Second Affiliated Hospital, Zhejiang University, School of Medicine | |
| Intravenous VAL-1221 Lafora Expanded Access Protocol (NCT05930223) | Parasail, LLC | |
| Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) | Northwest Biotherapeutics | |
| Expanded Access Program (EAP) STIMULAN VG (NCT06808568) | Biocomposites Ltd | |
| Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors (NCT06370013) | TransThera Sciences (Nanjing), Inc. | |
| Humanitarian Use of AVANTA Orthopaedics Proximal Interphalangeal Joint (NCT02244788) | Hospital for Special Surgery, New York | |
| Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome (NCT05795361) | Takeda | |
| Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release (NCT04771078) | Celgene | |
| Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA) (NCT06034886) | Biohaven Pharmaceuticals, Inc. | |
| Expanded Access to Tipifarnib (NCT04809233) | Kura Oncology, Inc. | |
| Managed Access Programs for ETB115, Eltrombopag (NCT04837703) | Novartis Pharmaceuticals | |
| Expanded Access to ABBV-706 (NCT07310277) | AbbVie | |
| Expanded Access to Burosumab (NCT03775187) | Kyowa Kirin Co., Ltd. | |
| Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI (NCT04513821) | Leonard-Meron Biosciences, Inc. | |
| Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders (NCT03626285) | OHSU Knight Cancer Institute | |
| An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315) (NCT07744113) | Alkermes, Inc. | |
| Expanded Access Program of Bitopertin For Participants With EPP or XLP (NCT07603401) | Disc Medicine, Inc | |
| Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease (NCT06931834) | RiboNova Inc. | |
| Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842) (NCT05466578) | Pfizer | |
| A Preliminary Study on Digital Learning Aids for Special Children With TRIZ and 3D Printing Technology (NCT05935462) | Taipei Medical University Shuang Ho Hospital | |
| Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI) (NCT03746899) | WideTrial, Inc. | |
| TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease (NCT03539380) | TauRx Therapeutics Ltd | |
| Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition (NCT07332338) | StemCyte, Inc. | |
| Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema (NCT06415448) | Ionis Pharmaceuticals, Inc. | |
| Expanded Access Program for GBM Subjects (NCT06676891) | Rznomics, Inc. | |
| Named Patient Program for Mitomycin for Pyelocalyceal Solution (NCT05494411) | UroGen Pharma Ltd. | |
| GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV (NCT03462810) | ViiV Healthcare | |
| Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use) (NCT06393660) | Victor Aquino | |
| Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors (NCT06834074) | Nuvalent Inc. | |
| Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy (NCT07119775) | AMO Pharma Limited | |
| Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency (NCT05911399) | Rare Thyroid Therapeutics International AB | |
| To Evaluate Oral Phase Swallowing Function Using Submental Ultrasound (NCT00752349) | National Taiwan University Hospital | |
| Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T) (NCT07380165) | IntraBio Inc | |
| Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol (NCT04400591) | Juno Therapeutics, a Subsidiary of Celgene | |
| An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC) (NCT07536815) | CytoDyn, Inc. | |
| Master Rollover Protocol for Continued Safety Assessment of Study Drug (NCT02632994) | Eli Lilly and Company | |
| Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries (NCT03327467) | Joanne Kurtzberg, MD | |
| Fremanezumab Managed Access Program for Pediatric Patients (NCT03539393) | Teva Branded Pharmaceutical Products R&D LLC | |
| Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents (NCT01995305) | Xiaofan Zhu | |
| Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma (NCT04571229) | Memorial Sloan Kettering Cancer Center | |
| Availability of Dibotatug (DR-01) Outside Clinical Trials Via Expanded Access for Eligible Participants (NCT07647627) | Dren Bio | |
| Named Patient Program for Olverembatinib (HQP1351) (NCT05594758) | Ascentage Pharma Group Inc. | |
| Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis (NCT05356052) | Bellerophon | |
| R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease (NCT03576690) | Regeneron Pharmaceuticals | |
| Expanded Access for ATB200/AT2221 for the Treatment of IOPD (NCT04327973) | Amicus Therapeutics | |
| Expanded Access to Venetoclax (NCT03123029) | AbbVie | |
| Managed Access Programs for TQJ230, Pelacarsen (NCT07000695) | Novartis Pharmaceuticals | |
| Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy (NCT07612930) | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | |
| Robot Assisted Physical Therapy for Pseudoparalysis in Massive Rotator Cuff Tear (NCT03905499) | Schulthess Klinik | |
| Compassionate Use of Concizumab if You Have Haemophilia (NCT04921956) | Novo Nordisk A/S | |
| Oral Green Tea Extract for Small Cell Lung Cancer (NCT01317953) | Shandong Cancer Hospital and Institute | |
| Expanded Access Protocol Using 131I-MIBG (NCT01590680) | Jubilant DraxImage Inc. | |
| Comparison of the Effects of Vaginal Cuff Closure Sexual Function in Laparoscopic Hysterectomy (NCT07228351) | Acibadem Kent Hospital | |
| Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors (NCT07675057) | Eli Lilly and Company | |
| Chelated Oral Iron Versus Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia Late in Pregnancy (NCT05151679) | Assiut University | |
| Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600) (NCT05522556) | Pfizer | |
| A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer (NCT04337099) | Matrix Biomed, Inc. | |
| Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma (NCT05346835) | Janssen Scientific Affairs, LLC | |
| Expanded Access to Gallium Maltolate (GaM) (NCT06404034) | Imaging Biometrics, LLC | |
| Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS (NCT05593185) | Sellas Life Sciences Group | |
| Continuation Protocol for Study Using Negative Pressure to Reduce Apnea Trial (NCT05608486) | Sommetrics, Inc. | |
| EAP for Deucrictibant Immediate-release (NCT07759141) | Pharvaris Netherlands B.V. | |
| Effect of Ultrasound Cavitation Versus Pneumatic Compression on Adipose Tissue Thickness on Lipedema Patients (NCT07404059) | Cairo University | |
| Individual Patient Compassionate Use of Mirdametinib (NCT05028166) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | |
| Individual Patient Compassionate Use of Crenolanib (NCT03620318) | Arog Pharmaceuticals, Inc. | |
| OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy (NCT02355782) | Michal Nowicki | |
| Evaluation of Different Serum Cartilage Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Subjects (NCT06757699) | Kocaeli University | |
| Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel (NCT05776160) | Kite, A Gilead Company | |
| Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT04777734) | argenx | |
| Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors (NCT06362590) | Seagen Inc. | |
| Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study (NCT07159464) | CSL Behring | |
| Post-Trial Access to ATH434 for Patients With Multiple System Atrophy (NCT07531433) | Alterity Therapeutics | |
| Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) (NCT05650476) | Pfizer | |